The capacity of S1R to simultaneously enhance energy production while triggering protective antioxidant mechanisms presents possibilities for therapeutic interventions targeting mitochondrial dysfunction in conditions such as AD and PD (Figure 1). Here, TMBIM4 is linked to Parkinson disease.